Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial-Reference-Cited by-同舟云学术

Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial

Published:2018-10 Issue: Volume:124 Page:293-297
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Lim Sung Won,Park Sehhoon,Kim Youjin,Cho Jang Ho,Park Song Ee,Lee Hansang,Kim Hee Kyung,Kim Sung Min,Sun Jong Mu,Lee Se-Hoon,Ahn Jin Seok,Park Keunchil,Ahn Myung-Ju

Funder

Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI)

Ministry of Health & Welfare, Republic of Korea

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference22 articles.

1. EGFR testing in lung cancer is ready for prime time;Hirsch;Lancet Oncol.,2009

2. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER);Shi;J. Thorac. Oncol.,2014

3. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial;Wu;Lancet Oncol.,2014

4. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial;Douillard;J. Clin. Oncol.,2010

5. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer;Jackman;J. Clin. Oncol.,2010

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T790M mutation sensitizes non-small cell lung cancer cells to radiation via suppressing SPOCK1;Biochemistry and Biophysics Reports;2024-07

2. Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08);Targeted Oncology;2024-01

3. Real-World Comparative Outcomes of Egfr-Tkis for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer;2024

4. A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non‐small cell lung cancer harboring EGFR mutations ( JMTO LC12 ‐01);Thoracic Cancer;2022-05-13

5. Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies;ESMO Open;2021-12